Immucell Corp risk profile
25 Normal where most of the sector sits
Measured 1 September 2026 from ICCC's filed statements. Recomputed nightly.
25 (Normal), driven by Market expectation at 53, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 53 | Elevated | Volatile | One-year price volatility — 52.2% |
| Operating pressure | 1 | Contained | Easing | Costs outgrowing revenue — -11.9 percentage points |
| Cash conversion | 47 | Elevated | Easing | Capital spending against operating cash — 0.51x |
| Leverage and coverage | 19 | Contained | Easing | Interest cover — 8.99x |
| Competitive position | 28 | Normal | Stable | R&D-intensity gap against peers — -39.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.